Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN

Abstract

<strong>Background and Objective:</strong> <em>BRAF</em> mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to <em>KRAS</em>. Oncogenic activating of BRAF mutations were studied lately in almost 0%-10% of prostate cancer cases. <br /><strong>Methods:</strong> In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. A hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. This study was done in pathology laboratory of Qaem Hospital during 2013-2015.<br /><strong>Results:</strong> Total number of 200 PC and normal cases was investigated for BRAF V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was not detected in normal cases. There were no significant differences between patient and control groups for this mutation (P>0.99). The frequency of BRAF V600E mutation was not significant in different age groups (P>0.285); the most frequency was related to the age range of 71-80. No significant difference was observed between tumor grade and BRAF mutation (P=0.21).<br /><strong>Conclusion:</strong> According to our findings, BRAF gene mutations did not play essential role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target for therapy.